Glenmark Pharmaceuticals on Monday said it has received approval from the US health regulator to market Sirolimus tablets, an immunosuppressant, in the American market.
The company''s US-based subsidiary has received final approval from the US Food and Drug Administration (USFDA) for the product which is a generic version of PF Prism CV''s Rapamune tablets, Glenmark Pharmaceuticals said in a statement.
Sirolimus tablets are prescribed for preventing rejection of kidney transplants either alone or with other medications.
According to IQVIA sales data for the 12-month period ending August 2020, the Rapamune achieved annual sales of around USD 119.7 million.
Glenmark said its current portfolio consists of 165 products authorised for distribution in the US marketplace and has 45 abbreviated new drug applications (ANDAs) pending with the USFDA for approval.
In addition to these internal filings, the company continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio, it added.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
